ALNYLAM PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q3 2024.
  • Alnylam Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$76.9M, a 136% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$188M, a 46.9% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$282M, a 64.1% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$785M, a 10.8% decline from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$709M, a 14.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$188M -$76.9M -$291M -136% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $103M $48.6M +$278M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$176M -$43.4M +$106M +71% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$282M -$116M +$72.2M +38.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$354M $214M +$472M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$826M -$230M -$38.1M -19.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$788M -$150M -$3.08M -2.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$785M -$189M +$5.95M +3.06% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$791M -$258M -$76.4M -42% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$715M -$192M -$45.5M -31.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$669M -$147M +$39.5M +21.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$709M -$195M -$339K -0.18% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$708M -$182M +$43.5M +19.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$752M -$146M +$52.7M +26.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 -$805M -$186M +$23.9M +11.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 -$828M -$194M +$104M +34.8% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$932M -$225M -$8.9M -4.12% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 -$923M -$199M +$37.4M +15.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$961M -$210M -$21.4M -11.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 -$939M -$298M -$77.7M -35.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-10
Q3 2019 -$862M -$216M +$38.3M +15% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$900M -$236M -$43.9M -22.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$856M -$189M -$41.4M -28.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$815M -$220M -$73.1M -49.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 -$742M -$255M -$129M -102% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 -$613M -$192M -$71.9M -59.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$541M -$147M -$40.9M -38.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$500M -$147M -$31.9M -27.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-13
Q3 2017 -$468M -$126M -$19.1M -17.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$449M -$120M -$28M -30.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$421M -$107M +$3.52M +3.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 -$425M -$115M -$22.9M -24.8% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-14
Q3 2016 -$402M -$107M -$28.3M -36.2% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$373M -$92.5M -$19.5M -26.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$354M -$110M -$57.8M -111% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q4 2015 -$296M -$92.5M -$46.8M -102% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-15
Q3 2015 -$249M -$78.3M -$33.1M -73.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 -$216M -$72.9M -$27.9M -62.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 -$188M -$52.2M +$217M +80.6% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-04
Q4 2014 -$405M -$45.7M -$16.1M -54.5% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-15
Q3 2014 -$389M -$45.2M -$13M -40.2% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 -$376M -$45M -$23.7M -111% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 -$352M -$269M -$259M -2644% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 -$92.9M -$29.6M +$58.8M +66.5% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-12
Q3 2013 -$152M -$32.2M -$14.1M -77.6% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-06
Q2 2013 -$138M -$21.3M -$9.25M -76.6% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-08
Q1 2013 -$128M -$9.8M +$1.09M +10% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 -$129M -$88.3M -$74.8M -550% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-13
Q3 2012 -$54.7M -$18.1M -$5.71M -45.9% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-07
Q2 2012 -$49M -$12.1M +$1.05M +8.01% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 -$50M -$10.9M +$4.78M +30.5% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-07
Q4 2011 -$54.8M -$13.6M -$1.18M -9.48% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-20
Q3 2011 -$53.6M -$12.4M -$3.71M -42.5% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-05
Q2 2011 -$49.9M -$13.1M -$1.49M -12.8% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-08
Q1 2011 -$48.4M -$15.7M -$4.37M -38.7% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-03
Q4 2010 -$44.1M -$12.4M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-19
Q3 2010 -$8.73M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$11.6M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-03
Q1 2010 -$11.3M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.